Free Trial
NASDAQ:VIRI

Virios Therapeutics (VIRI) Stock Price, News & Analysis

Virios Therapeutics logo
$1.30 -0.07 (-5.11%)
As of 10/13/2026

About Virios Therapeutics Stock (NASDAQ:VIRI)

Advanced

Key Stats

Today's Range
$1.29
▼
$1.38
50-Day Range
$1.35
▼
$2.68
52-Week Range
$0.13
▼
$1.04
Volume
110,445 shs
Average Volume
1.05 million shs
Market Capitalization
$25.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Virios Therapeutics, Inc. (NASDAQ: VIRI) is a clinical-stage biotechnology company focused on developing treatments for diseases associated with abnormal immune responses to latent viral infections. The company’s research has primarily centered on fibromyalgia, a chronic condition characterized by widespread pain and other symptoms.

Virios Therapeutics’ lead product candidate is IMC-1, a fixed-dose combination of famciclovir, an antiviral medicine, and celecoxib, an anti-inflammatory medicine. The company has evaluated IMC-1 in clinical studies for fibromyalgia and has investigated the potential role of antiviral and anti-inflammatory treatment in addressing the underlying mechanisms of the disease.

Founded in 2018, Virios Therapeutics has focused its development activities on the U.S. market and on advancing therapies for conditions with significant unmet medical needs. As a clinical-stage company, its products remain subject to clinical development and regulatory review and are not broadly marketed pharmaceuticals.

AI Generated. May Contain Errors.

Receive VIRI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Virios Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VIRI Stock News Headlines

Virios Therapeutics (NASDAQ:VIRI) Stock Falls 2.1% - Here's Why
Dogwood Therapeutics Inc (DWTX)
Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered. Buried inside is what some call the legal groundwork for the biggest change to American money in over a century, with a key Treasury vote potentially as soon as January 18. Ian King, Chief Strategist at Strategic Fortunes, breaks down what the order could mean for the dollar and the financial system.tc pixel
Dogwood prices 578,950 shares at $8.26 in registered direct offering
Dogwood announces conversion of existing $19.5M in debt to equity
DWTX Stock trading resumes
Dogwood Therapeutics, Inc. (DWTX)
DWTX Stock trading halted, volatility trading pause
See More Headlines

VIRI Stock Analysis - Frequently Asked Questions

Virios Therapeutics' stock was trading at $4.16 at the start of the year. Since then, VIRI stock has decreased by 68.8% and is now trading at $1.30.

Virios Therapeutics, Inc. (NASDAQ:VIRI) announced its earnings results on Thursday, August, 8th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.02.

Virios Therapeutics (VIRI) raised $30 million in an initial public offering on Thursday, December 17th 2020. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.

Shares of VIRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Virios Therapeutics investors own include Atossa Genetics (ATOS), Beyond Meat (BYND), Palantir Technologies (PLTR), SNDL (SNDL), Tiziana Life Sciences (TLSA), AMC Entertainment (AMC) and Ford Motor (F).

Company Calendar

Last Earnings
8/08/2024
Today
10/14/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:VIRI
CIK
1818844
Fax
N/A
Employees
5
Year Founded
2012

Profitability

EPS (Trailing Twelve Months)
($0.27)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$5.30 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-130.33%
Return on Assets
-115.00%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.27
Quick Ratio
7.27

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.20 per share
Price / Book
6.50

Miscellaneous

Outstanding Shares
19,258,000
Free Float
16,909,000
Market Cap
$25.04 million
Optionable
No Data
Beta
1.58

Social Links

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:VIRI) was last updated on 10/13/2026 by MarketBeat.com Staff.
From Our Partners